ERBB2 and neoplasm: Subsequently, in a phase I basket trials including patients with HER2-positive refractory solid tumors, none of six CRC patients experienced an objective response to the combination of paclitaxel, interleukin-12, and trastuzumab [137] and only two of the eight CRC patients had a partial response to the association of cetuximab and lapatinib while in the absence of complete tumor regression [138].